Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) announced that the company and its subsidiaries Chengdu Shengdi Pharmaceutical Co., Ltd. and Tianjin Hengrui Pharmaceutical Co., Ltd. have received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-4357 injections and HRS-5041 tablets, and will conduct clinical trials in the near future. Specifically, an open, multicenter, phase Ib/II clinical study on the safety, tolerability and initial efficacy of HRS-4357 combined with HRS-5041 in the treatment of PSMA-positive prostate cancer.

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) announced that the company and its subsidiaries Chengdu Shengdi Pharmaceutical Co., Ltd. and Tianjin Hengrui Pharmaceutical Co., Ltd. have received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-4357 injections and HRS-5041 tablets, and will conduct clinical trials in the near future. Specifically, an open, multicenter, phase Ib/II clinical study on the safety, tolerability and initial efficacy of HRS-4357 combined with HRS-5041 in the treatment of PSMA-positive prostate cancer.